The turmoil in Congress over the Jeffrey Epstein probe isn't going away anytime soon after the House Speaker ended the legislative session early before the August break.

It wasn't perfect for Johnson, who struggled in one of his five summer league games to total just five points on 2-of-10 shooting from the field and 0-of-5 shooting from three-point range in the Heat's loss to the Cleveland Cavaliers on July 13 in Las Vegas. He also shot under 30% from behind the arc during his five summer league appearances.

Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish technical momentum. Learn more on JNJ stock here.

We recently published 10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ)’s shares are up by 5% since its latest earnings report,

Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release. The agreement adds Zilretta, an injectable osteoarthritis treatment, to Johnson & Johnson’s portfolio.

Johnson & Johnson MedTech expanded its campus in Santa Clara as it continues to invest in robotically-assisted surgery devices.

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and profit forecast on Wednesday after a strong quarter for flagship cancer drug Darzalex and its cardiovascular devices.